Mechanisms of local immunosuppression in cutaneous melanoma.
about
Targeting microRNAs as key modulators of tumor immune responseThe IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cellsActivation of tonsil dendritic cells with immuno-adjuvants.Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerTargeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic miceMetastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.Pathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppressionCurrent concepts of metastasis in melanoma.Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanomaDetection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.Melanoma in immunosuppressed patientsSentinel node and mechanism of lymphatic metastasis.Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells.The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Lessons from cancer immunoediting in cutaneous melanoma.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.The immune escape in melanoma: role of the impaired dendritic cell function.The oncolytic virus ΔPK has multimodal anti-tumor activity.Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomachThe HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins.Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8(+) T-cell responses.New insights on the role of CD8(+)CD57(+) T-cells in cancer.Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competenceImmunomodulatory effects of radiofrequency ablation in a breast cancer model.Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis.Local immune response predicts survival in patients with thick (t4) melanomas.Re-inventing intratumoral immunotherapy for melanoma.Immune system and melanoma biology: a balance between immunosurveillance and immune escape.MicroRNAs in the Diagnosis and Treatment of Cancer.LW106, A Novel Inhibitor of IDO1, Suppresses Tumor Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in the Tumor Microenvironment.Immunotolerant indoleamine-2,3-dioxygenase is increased in condyloma acuminata.Role of IL-10 and TGF-β in melanoma.Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.Intratumoral TLR-4 Agonist Injection Is Critical for Modulation of Tumor Microenvironment and Tumor Rejection
P2860
Q26746972-3B7D06C3-8461-4614-B742-6A10EB8432E8Q28275608-FE46E02A-5042-4B3C-B7FA-1F42B0CF440BQ33325670-A65FDC24-9E1F-4908-9E25-72BFA59C2BCAQ33482453-9F9CBEC9-05B9-4B20-833B-18C5A4C73004Q33614407-3EFBBDD6-C0ED-4E88-9907-16DF730567AEQ34002125-EC8EF64D-ABFD-4065-8E80-16293EA8D796Q34117595-A7F991EB-BA99-49BB-B904-BB670346F042Q34610427-10392CD8-078D-46C9-811C-30B9FB17C115Q35145392-7173A956-56D3-47A0-A7F0-4E4176C9538AQ35234354-12BCC837-2D64-4A7E-B92E-92A6AD9E1EF8Q35931423-6458F9DB-3993-4CDB-BCFD-7D09BC20DC4CQ36512842-EB4BEDB0-E7BB-45C4-8A51-6D2C0137EBB0Q36679422-C0FAA4ED-05AD-48F0-8C41-00C5C5DBD36CQ36973676-9076C2D7-2A03-47D2-8FFB-3637DC0E36AAQ37028329-06D495F6-C113-410B-A24C-CBD5A0FBE362Q37329058-764FF08E-DC59-4366-B17E-222BF6FC8417Q37522460-02823B40-F170-4766-9018-2D0A74E912F9Q37952804-DEA0D353-AC0F-45EE-890E-4ADD49E0F78AQ38038176-4EA27D92-68FE-4AE4-89D0-A29A6129E99BQ38047057-B769C344-27B7-4379-8FE3-AC74071E8EEFQ38250071-181A20D1-7EF9-4450-97CE-2A1DD9D22D7DQ38848885-2BC2C475-FC92-448F-91B6-7B72DDD92920Q39351950-822A39B4-A06C-48AC-A154-3CEAE9D4C71DQ39792514-0E980C34-76B6-46E5-9C0C-90569DF2E23BQ40953830-F127DF93-CD26-494E-B1A0-42C95249AD13Q41474870-115A25D5-AC77-4A48-AA34-069174AE18DBQ42112527-E9855B23-998C-49A1-8E73-CF216E1E6603Q42698829-48DE97C4-C7D8-4314-A0A8-D84EB68C2798Q43197760-592E9801-B55C-4ED8-B999-A0BA9180129FQ44287609-0F002987-9B96-4420-828E-1203FE45ED7FQ44512595-EF6A84AE-01E8-4AEF-82D5-8C2138FA434CQ44607083-AD6E6249-4350-4040-9133-F3F1128ACF07Q49166036-9AC4A170-0FA5-4801-BDEC-F3885FF5CF46Q50067809-4FB17BC9-181D-41D4-8CC9-BED859A5B969Q52714204-745BCF33-7AC1-4A19-BC4C-E28620DBA890Q52797663-035CC9A0-27C5-47FE-A5E7-D6C205A0593AQ52870717-CCF7B476-C33F-4C5D-94E8-211D1DB462CCQ55346219-4811339D-E02B-464C-99CC-28C6146BC2F9Q58905402-FAD8290B-C9FD-4AA1-9C21-1C0B82521D70
P2860
Mechanisms of local immunosuppression in cutaneous melanoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of local immunosuppression in cutaneous melanoma.
@en
type
label
Mechanisms of local immunosuppression in cutaneous melanoma.
@en
prefLabel
Mechanisms of local immunosuppression in cutaneous melanoma.
@en
P2093
P2860
P356
P1476
Mechanisms of local immunosuppression in cutaneous melanoma
@en
P2093
D McCormick
F G Gabriel
N J Borthwick
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603763
P407
P577
2007-06-12T00:00:00Z